683 Capital Management’s Vigil Neuroscience VIGL Stock Holding History

683 Capital Management’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,261,772	Closed	-$10M	–	159
2025 Q2	$10M	Sell	1,261,772 -478,228	-27%	-$2.14M	0.66%	42
2025 Q1	$3.1M	Buy	1,740,000 +340,000	+24%	+$763K	0.21%	95
2024 Q4	$2.38M	Buy	1,400,000 +180,420	+15%	+$533K	0.15%	84
2024 Q3	$4.15M	Buy	1,219,580 +119,580	+11%	+$443K	0.32%	69
2024 Q2	$4.4M	Buy	1,100,000 +105,100	+11%	+$360K	0.33%	64
2024 Q1	$3.39M	Buy	+994,900	New	+$3.11M	0.25%	68
2023 Q2	–	Sell	-15,092	Closed	-$148K	–	251
2023 Q1	$148K	Hold	15,092	–	–	0.01%	207
2022 Q4	$189K	Buy	+15,092	New	+$185K	0.02%	180

Other funds holding VIGL

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

683 Capital Management's VIGL Position: Q3 2025 in Review

683 Capital Management sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 1,261,772 shares — an estimated $10M sold.

683 Capital Management first reported a position in VIGL in Q4 2022 and held it in 8 quarters. The position peaked at $10M in Q2 2025. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.

683 Capital Management reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
683 Capital Management sold 1,261,772 Vigil Neuroscience shares in Q3 2025, an estimated $10M.
683 Capital Management first reported a position in Vigil Neuroscience in Q4 2022 and held it in 8 quarters.
683 Capital Management's Vigil Neuroscience position peaked at $10M in Q2 2025.
2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.

Based on 683 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.